Cell Biotech쎌바이오텍
049960 · KOSDAQ · ₩049960 · 쎌바이오텍
₩14,910▼ ₩90 (0.60%)End-of-day · Oct 27, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | 72.8% | 72.7% | 72.2% | 72.5% | 75.1% | 76.1% |
| Operating margin | 16.7% | 14.9% | 13.6% | 4.1% | 12.0% | 15.5% |
| Net margin | 27.8% | 19.1% | 30.3% | 11.7% | 16.4% | 22.2% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | +13.7% | +6.4% | −7.2% | +6.5% | +7.8% | — |
| Operating income growth | +27.6% | +16.4% | +209.6% | −63.7% | −16.6% | — |
| Net income growth | +65.9% | −33.1% | +140.0% | −23.9% | −20.3% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | 12.5% | 7.9% | 12.8% | 5.7% | 7.7% | 9.7% |
| Return on assets | 9.6% | 7.6% | 12.2% | 5.4% | 7.2% | 9.2% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 6.0% | 3.7% | 5.0% | 5.1% | 7.2% | 5.8% |
| Net debt to equity | — | — | — | — | — | — |
| Current ratio | 1,353.4% | 2,133.7% | 1,657.0% | 1,699.3% | 1,023.9% | 1,171.0% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: Cell Biotech / 쎌바이오텍 / 049960 / KRX:049960
Source: KRX statistical information